Csenge Advisory Group Eli Lilly & CO Transaction History

Csenge Advisory Group

$1.74 Billion
Q2 2024

A detailed history of Csenge Advisory Group transactions in Eli Lilly & CO stock. As of the latest transaction made, Csenge Advisory Group holds 5,566 shares of LLY stock, worth $4.88 Million. This represents 0.29% of its overall portfolio holdings.

Number of Shares

5,566

Previous 5,145 8.18%

Holding current value

$4.88 Million

Previous $4 Million 25.91%

% of portfolio

0.29%

Previous 0.23%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 10, 2024	BUY	$724.87 - $909.04 $305,170 - $382,705	421 Added 8.18%	5,566 $5.04 Million
Q1 2024 May 03, 2024	BUY	$592.2 - $792.28 $552,522 - $739,197	933 Added 22.15%	5,145 $4 Million
Q4 2023 Feb 13, 2024	BUY	$525.19 - $619.13 $38,338 - $45,196	73 Added 1.76%	4,212 $2.46 Million
Q3 2023 Nov 01, 2023	BUY	$434.7 - $599.3 $3,912 - $5,393	9 Added 0.22%	4,139 $2.22 Million
Q2 2023 Jul 20, 2023	BUY	$350.74 - $468.98 $234,645 - $313,747	669 Added 19.33%	4,130 $1.94 Million
Q1 2023 May 01, 2023	SELL	$310.63 - $364.82 $4,348 - $5,107	-14 Reduced 0.4%	3,461 $1.19 Million
Q4 2022 Feb 10, 2023	SELL	$321.55 - $374.67 $180,068 - $209,815	-560 Reduced 13.88%	3,475 $1.27 Million
Q3 2022 Oct 04, 2022	BUY	$296.48 - $337.87 $7,708 - $8,784	26 Added 0.65%	4,035 $1.31 Million
Q2 2022 Jul 27, 2022	BUY	$278.73 - $327.27 $92,538 - $108,653	332 Added 9.03%	4,009 $1.3 Million
Q1 2022 May 09, 2022	BUY	$234.69 - $291.66 $235,159 - $292,243	1,002 Added 37.46%	3,677 $1.05 Million
Q4 2021 Feb 10, 2022	SELL	$224.85 - $279.04 $372,126 - $461,811	-1,655 Reduced 38.22%	2,675 $618,000
Q3 2021 Oct 20, 2021	BUY	$221.6 - $272.71 $366,748 - $451,335	1,655 Added 61.87%	4,330 $994,000
Q2 2021 Jul 21, 2021	SELL	$180.55 - $233.54 $133,968 - $173,286	-742 Reduced 21.71%	2,675 $618,000
Q1 2021 Apr 28, 2021	SELL	$164.32 - $212.72 $355,424 - $460,113	-2,163 Reduced 38.76%	3,417 $630,000
Q4 2020 Jan 26, 2021	SELL	$130.46 - $172.63 $124,067 - $164,171	-951 Reduced 14.56%	5,580 $942,000
Q3 2020 Nov 09, 2020	BUY	$146.22 - $169.13 $48,691 - $56,320	333 Added 5.37%	6,531 $941,000
Q2 2020 Jul 17, 2020	BUY	$136.42 - $164.18 $316,494 - $380,897	2,320 Added 59.82%	6,198 $1.02 Million
Q1 2020 Apr 21, 2020	BUY	$119.05 - $147.35 $12,857 - $15,913	108 Added 2.86%	3,878 $538,000
Q4 2019 Feb 05, 2020	BUY	$106.92 - $132.43 $20,742 - $25,691	194 Added 5.43%	3,770 $495,000
Q3 2019 Nov 14, 2019	BUY	$106.79 - $116.16 $381,881 - $415,388	3,576 New	3,576 $400,000
Q1 2019 May 07, 2019	SELL	$111.31 - $131.02 $203,585 - $239,635	-1,829 Closed	0 $0
Q4 2018 Feb 07, 2019	BUY	$105.9 - $118.64 $137,670 - $154,232	1,300 Added 245.75%	1,829 $211,000
Q3 2018 Nov 19, 2018	BUY	$85.86 - $107.31 $45,419 - $56,766	529 New	529 $58,000

Others Institutions Holding LLY

# of Institutions

3,872

Shares Held

751M

Call Options Held

6.34M

Put Options Held

7.97M

View Full List

About ELI LILLY & Co

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $834B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

More about LLY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Csenge Advisory Group, based on Form 13F filings with the SEC.

News

Stay updated on Csenge Advisory Group with notifications on news.

Account

Csenge Advisory Group Eli Lilly & CO Transaction History